Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05193409 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
A Phase 2 study, sponsored by Bionomics Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT05193409: Completed Phase 2 study, sponsored by Bionomics Limited.
NCT05193409 is a Phase 2 study that has completed, run by Bionomics Limited. The registered enrollment target is 151 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05193409, a Phase 2 study, has completed, sponsored by Bionomics Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).
Primary Outcome
The SUDS is a self reported measure of the intensity of distress currently experienced by an individual. The range is 0-100, with a higher score indicating a higher level of anxiety/greater distress.
Interventions
- DRUG Placebo
- DRUG 225 mg BNC210
- DRUG 675 mg BNC210
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2022-10-17 |
| Phase | Phase 2 |
What the finished NCT05193409 record still lists
NCT05193409 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05193409 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05193409 about?
NCT05193409 is a clinical study titled "A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder". The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).
What is the current status of trial NCT05193409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2022-02-02. Estimated completion is 2022-10-17.
What interventions are being tested in trial NCT05193409?
The interventions under investigation include: Placebo (DRUG), 225 mg BNC210 (DRUG), 675 mg BNC210 (DRUG).
Who is sponsoring clinical trial NCT05193409?
This trial is sponsored by Bionomics Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05193409's enrollment target sits among peer trials
151 454th of 2000 higher than 1,546 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI